111, Inc. Sponsored ADR
YI Healthcare Medical Distribution
111, Inc. Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $1.8 billion, down 9.00% from fiscal 2024. In the quarter to March 2026, revenue fell 29.6%, EPS fell 200.0%, free cash flow fell 185.7% and total debt rose 82.5%, each against the same quarter a year earlier.
Follow YI
111, Inc. Sponsored ADR (YI) Piotroski F-score
111, Inc. Sponsored ADR's Piotroski F-score for fiscal 2025 is 5 out of 9: 5 of nine tests of profitability, leverage and efficiency passed, down from 7 in fiscal 2024.
Piotroski F-score, annual
Embed this chart
Annual newest first
| Period | Piotroski F-score | Change (points) |
|---|---|---|
| FY2025 | 5 | (2.00) |
| FY2024 | 7 | 4.00 |
| FY2023 | 3 | (1.00) |
| FY2022 | 4 | 1.00 |
| FY2021 | 3 | (2.00) |
| FY2020 | 5 | 2.00 |
| FY2019 | 3 | (1.00) |
| FY2018 | 4 | — |
How fiscal 2025’s score is made up
| Test | This year | Year before | Result | Points |
|---|---|---|---|---|
| Positive return on assets | (2.73%) | (2.17%) | Fail | 0 |
| Positive operating cash flow | 17.04m | 36.03m | Pass | 1 |
| Rising return on assets | (2.73%) | (2.17%) | Fail | 0 |
| Cash flow above net income | 26.53m | 44.90m | Pass | 1 |
| Falling long-term leverage | 0.00 | 0.00 | Pass | 1 |
| Rising current ratio | 1.09 | 1.13 | Fail | 0 |
| No new shares issued | 8,701,300 | 8,592,000 | Fail | 0 |
| Rising gross margin | 5.76% | 5.76% | Pass | 1 |
| Rising asset turnover | 5.16 | 4.83 | Pass | 1 |
| Piotroski F-score | Mixed | 5 | ||
How the Piotroski F-score works
One point for each of nine tests, this fiscal year against the one before: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, a rising current ratio, no new shares issued, a rising gross margin and rising asset turnover. The ratios are the ones on this site, so each can be checked.
Joseph Piotroski (2000) called 8–9 high and 0–1 low; reading it in three bands is the common convention:
| 7–9 | Strong — most fundamentals improved |
|---|---|
| 4–6 | Mixed |
| 0–3 | Weak — most fundamentals deteriorated |
Where this differs from the paper: return on assets is on average rather than beginning-of-year assets, and weighted basic shares stand in for shares issued. The score is shown only when all nine tests can be worked out, which takes three fiscal years; banks and insurers, which report no current assets or gross profit, have none.
Piotroski F-score against peers
| Company | Piotroski F-score |
|---|---|
| CAH Cardinal Health, Inc. compare | 7 |
| YI 111, Inc. Sponsored ADR | 5 |
| COSM Cosmos Health Inc. compare | 5 |
| AHG Akso Health Group Sponsored ADR compare | 5 |
| HSIC Henry Schein, Inc. compare | 5 |
| FOCL FocalTherics compare | 3 |
| HKPD Cellyan Biotechnology Co., Ltd compare | 3 |
| SNYRQ Synergy CHC Corp. compare | 2 |
| ACH Accendra Health, Inc. compare | 2 |
What Piotroski F-score is
The Piotroski F-Score tells an investor how many signs of improving profitability, funding and efficiency a company shows against a year earlier.
One point for each of nine tests against a year earlier: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, rising current ratio, no new shares issued, rising gross margin, and rising asset turnover